Introduction – Company Background
GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.
With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.
With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.
From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.
At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.
By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.
Core Strengths in Insole Manufacturing
At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.
Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.
We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.
With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.
Customization & OEM/ODM Flexibility
GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.
Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.
With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.
Quality Assurance & Certifications
Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.
We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.
Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.
ESG-Oriented Sustainable Production
At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.
To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.
We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.
Let’s Build Your Next Insole Success Together
Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.
From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.
Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.
🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw
Arch support insole OEM from Indonesia
Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.
With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Vietnam flexible graphene product manufacturing
Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.
We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.ODM pillow factory in Taiwan
At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Graphene insole OEM factory Vietnam
📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.PU insole OEM production in Taiwan
A new CRISPR gene-editing tool, AsCas12f, smaller than the commonly used Cas9, has been engineered for better efficiency and effectiveness in treating genetic disorders. Tested successfully in mice, this tool could lead to more compact and efficient genome-editing applications in humans. The newly designed CRISPR enzyme offers a more compact DNA editing solution, maintaining the efficiency of existing tools and could improve patient treatment. A new CRISPR-based gene-editing tool has been developed which could lead to better treatments for patients with genetic disorders. The tool is an enzyme, AsCas12f, which has been modified to offer the same effectiveness but at one-third the size of the Cas9 enzyme commonly used for gene editing. The compact size means that more of it can be packed into carrier viruses and delivered into living cells, making it more efficient. Researchers created a library of possible AsCas12f mutations and then combined selected ones to engineer an AsCas12f enzyme with 10 times more editing ability than the original unmutated type. This engineered AsCas12f has already been successfully tested in mice and has the potential to be used for new, more effective treatments for patients in the future. The team used cryogenic electron microscopy, a method to look at the structure of biological molecules in high-resolution, to analyze AsCas12f and engineer their new version. The DMS “heatmap” illustrates how all single mutations affected genome-editing activity. Blue squares indicate an undesirable mutation, while red ones represent desirable changes. The darker the color, the greater the effect. Credit: Hino et al. 2023 The Evolution of CRISPR Technology By now you have probably heard of CRISPR, the gene-editing tool which enables researchers to replace and alter segments of DNA. Like genetic tailors, scientists have been experimenting with “snipping away” the genes that make mosquitoes malaria carriers, altering food crops to be more nutritious and delicious, and in recent years begun human trials to overcome some of the most challenging diseases and genetic disorders. The potential of CRISPR to improve our lives is so phenomenal that in 2020, researchers Jennifer Doudna and Emmanuelle Charpentier, who developed the most precise version of the tool named CRISPR-Cas9, were awarded the Nobel Prize in chemistry. But even Cas9 has limitations. The common way to deliver genetic material into a host cell is to use a modified virus as a carrier. Adeno-associated viruses (AAVs) are not harmful to patients, can enter many different types of cells to introduce CRISPR enzymes like Cas9, and have a lower likelihood of provoking an undesired immune response compared to some other methods. However, like any parcel delivery service, there is a size limit. “Cas9 is at the very limit of this size restriction, so there has been a demand for a smaller Cas protein that can be efficiently packaged into AAV and serve as a genome-editing tool,” explained Professor Osamu Nureki from the Department of Biological Sciences at the University of Tokyo. This graph shows how efficient two versions of the engineered AsCas12f enzyme are at gene editing (second and third columns in orange and yellow), compared to the original unengineered type (first column in gray), and the commonly used Cas9 type (fourth column in blue). The higher the bar, the more efficient the tool. Credit: Hino et al. 2023 A Smaller, More Effective CRISPR Enzyme Its large size means that Cas9 can lack efficiency when used for gene therapy. So, a large multi-institutional team worked to develop a smaller Cas enzyme that is just as active, but more efficient. The researchers selected an enzyme called AsCas12f, from the bacteria Axidibacillus sulfuroxidans. The advantage of this enzyme is that it is one of the most compact Cas enzymes found to date and less than one-third the size of Cas9. However, in previous tests it showed barely any genome activity in human cells. “Using a screening method called deep mutational scanning, we assembled a library of potential new candidates by substituting each amino acid residue of AsCas12f with all 20 types of amino acids on which all life is based. From this, we identified over 200 mutations that enhanced genome-editing activity,” explained Nureki. “Based on insights gained from the structural analysis of AsCas12f, we selected and combined these enhanced-activity amino acid mutations to create a modified AsCas12f. This engineered AsCas12f has more than 10 times the genome-editing activity compared to the usual AsCas12f type and is comparable to Cas9, while maintaining a much smaller size.” The team has already carried out animal trials with the engineered AsCas12f system, partnering it with other genes and administering it to live mice. Administering treatments directly into the body is preferable to extracting cells, editing them in a lab, and reinserting them into patients, which is more time-intensive and costly. The success of the tests showed that engineered AsCas12f has the potential to be used for human gene therapies, such as treating hemophilia, a disease in which the blood does not clot normally. The team discovered numerous potentially effective combinations for engineering an improved AsCas12f gene-editing system, so the researchers acknowledge the possibility that the selected mutations may not have been the most optimal of all the available mixes. As a next step, computational modeling or machine learning could be used to sift through the combinations and predict which might offer even better improvements. “Elevating AsCas12f to exhibit genome-editing activity comparable to that of Cas9 is a significant achievement and serves as a substantial step in the development of new, more compact genome-editing tools,” said Nureki. “For us, the crucial aspect of gene therapy is its potential to genuinely help patients. Using the engineered AsCas12f we developed, our next challenge is to actually administer gene therapy to aid people suffering from genetic disorders.” Reference: “An AsCas12f-based compact genome-editing tool derived by deep mutational scanning and structural analysis” by Tomohiro Hino, Satoshi N. Omura, Ryoya Nakagawa, Tomoki Togashi, Satoru N. Takeda, Takafumi Hiramoto, Satoshi Tasaka, Hisato Hirano, Takeshi Tokuyama, Hideki Uosaki, Soh Ishiguro, Madina Kagieva, Hiroyuki Yamano, Yuki Ozaki, Daisuke Motooka, Hideto Mori, Yuhei Kirita, Yoshiaki Kise, Yuzuru Itoh, Satoaki Matoba, Hiroyuki Aburatani, Nozomu Yachie, Tautvydas Karvelis, Virginijus Siksnys, Tsukasa Ohmori, Atsushi Hoshino and Osamu Nureki, 29 September 2023, Cell. DOI: 10.1016/j.cell.2023.08.031 Funding: Research Council of Lithuania for the support of European Joint Programme on Rare Diseases project GET-READY, Japan Foundation for Applied Enzymology, AMED, AMED, Platform Project for Supporting Drug Discovery and Life Science Research from AMED, Cabinet Office, Government of Japan, Public/Private R&D Investment Strategic Expansion Program (PRISM)
Researchers have developed RNA-based predictive models that use artificial intelligence to determine the on- and off-target activity of CRISPR tools that target RNA rather than DNA. The model is designed to facilitate precise control of gene expression, which could revolutionize the development of new CRISPR-based therapies. Researchers have developed an artificial intelligence model, TIGER, that predicts the on- and off-target activity of RNA-targeting CRISPR tools. This innovation, detailed in a study published in Nature Biotechnology, can accurately design guide RNAs, modulate gene expression, and is poised to drive advancements in CRISPR-based therapies. Artificial intelligence can predict on- and off-target activity of CRISPR tools that target RNA instead of DNA, according to new research published today (July 3) in the journal Nature Biotechnology. The study by researchers at New York University, Columbia Engineering, and the New York Genome Center, combines a deep learning model with CRISPR screens to control the expression of human genes in different ways—such as flicking a light switch to shut them off completely or by using a dimmer knob to partially turn down their activity. These precise gene controls could be used to develop new CRISPR-based therapies. CRISPR is a gene editing technology with many uses in biomedicine and beyond, from treating sickle cell anemia to engineering tastier mustard greens. It often works by targeting DNA using an enzyme called Cas9. In recent years, scientists discovered another type of CRISPR that instead targets RNA using an enzyme called Cas13. The Potential of RNA-Targeting CRISPRs RNA-targeting CRISPRs can be used in a wide range of applications, including RNA editing, knocking down RNA to block expression of a particular gene, and high-throughput screening to determine promising drug candidates. Researchers at NYU and the New York Genome Center created a platform for RNA-targeting CRISPR screens using Cas13 to better understand RNA regulation and to identify the function of non-coding RNAs. Because RNA is the main genetic material in viruses including SARS-CoV-2 and flu, RNA-targeting CRISPRs also hold promise for developing new methods to prevent or treat viral infections. Also, in human cells, when a gene is expressed, one of the first steps is the creation of RNA from the DNA in the genome. A key goal of the study is to maximize the activity of RNA-targeting CRISPRs on the intended target RNA and minimize activity on other RNAs which could have detrimental side effects for the cell. Off-target activity includes both mismatches between the guide and target RNA as well as insertion and deletion mutations. Earlier studies of RNA-targeting CRISPRs focused only on on-target activity and mismatches; predicting off-target activity, particularly insertion and deletion mutations, has not been well-studied. In human populations, about one in five mutations are insertions or deletions, so these are important types of potential off-targets to consider for CRISPR design. “Similar to DNA-targeting CRISPRs such as Cas9, we anticipate that RNA-targeting CRISPRs such as Cas13 will have an outsized impact in molecular biology and biomedical applications in the coming years,” said Neville Sanjana, associate professor of biology at NYU, associate professor of neuroscience and physiology at NYU Grossman School of Medicine, a core faculty member at New York Genome Center, and the study’s co-senior author. “Accurate guide prediction and off-target identification will be of immense value for this newly developing field and therapeutics.” In their study in Nature Biotechnology, Sanjana and his colleagues performed a series of pooled RNA-targeting CRISPR screens in human cells. They measured the activity of 200,000 guide RNAs targeting essential genes in human cells, including both “perfect match” guide RNAs and off-target mismatches, insertions, and deletions. Sanjana’s lab teamed up with the lab of machine learning expert David Knowles to engineer a deep learning model they named TIGER (Targeted Inhibition of Gene Expression via guide RNA design) that was trained on the data from the CRISPR screens. Comparing the predictions generated by the deep learning model and laboratory tests in human cells, TIGER was able to predict both on-target and off-target activity, outperforming previous models developed for Cas13 on-target guide design and providing the first tool for predicting off-target activity of RNA-targeting CRISPRs. How Machine Learning Improves CRISPR Guide Design “Machine learning and deep learning are showing their strength in genomics because they can take advantage of the huge datasets that can now be generated by modern high-throughput experiments. Importantly, we were also able to use “interpretable machine learning” to understand why the model predicts that a specific guide will work well,” said Knowles, assistant professor of computer science and systems biology at Columbia Engineering, a core faculty member at New York Genome Center, and the study’s co-senior author. “Our earlier research demonstrated how to design Cas13 guides that can knock down a particular RNA. With TIGER, we can now design Cas13 guides that strike a balance between on-target knockdown and avoiding off-target activity,” said Hans-Hermann (Harm) Wessels, the study’s co-first author and a senior scientist at the New York Genome Center, who was previously a postdoctoral fellow in Sanjana’s laboratory. The researchers also demonstrated that TIGER’s off-target predictions can be used to precisely modulate gene dosage—the amount of a particular gene that is expressed—by enabling partial inhibition of gene expression in cells with mismatch guides. This may be useful for diseases in which there are too many copies of a gene, such as Down syndrome, certain forms of schizophrenia, Charcot-Marie-Tooth disease (a hereditary nerve disorder), or in cancers where aberrant gene expression can lead to uncontrolled tumor growth. “Our deep learning model can tell us not only how to design a guide RNA that knocks down a transcript completely, but can also ‘tune’ it—for instance, having it produce only 70% of the transcript of a specific gene,” said Andrew Stirn, a PhD student at Columbia Engineering and the New York Genome Center, and the study’s co-first author. By combining artificial intelligence with an RNA-targeting CRISPR screen, the researchers envision that TIGER’s predictions will help avoid undesired off-target CRISPR activity and further spur development of a new generation of RNA-targeting therapies. “As we collect larger datasets from CRISPR screens, the opportunities to apply sophisticated machine learning models are growing rapidly. We are lucky to have David’s lab next door to ours to facilitate this wonderful, cross-disciplinary collaboration. And, with TIGER, we can predict off-targets and precisely modulate gene dosage which enables many exciting new applications for RNA-targeting CRISPRs for biomedicine,” said Sanjana. Reference: “Prediction of on-target and off-target activity of CRISPR–Cas13d guide RNAs using deep learning” by Hans-Hermann Wessels, Andrew Stirn, Alejandro Méndez-Mancilla, Eric J. Kim, Sydney K. Hart, David A. Knowles and Neville E. Sanjana, 3 July 2023, Nature Biotechnology. DOI: 10.1038/s41587-023-01830-8 Additional study authors include Alejandro Méndez-Mancilla and Sydney K. Hart of NYU and the New York Genome Center, and Eric J. Kim of Columbia University. The research was supported by grants from the National Institutes of Health (DP2HG010099, R01CA218668, R01GM138635), DARPA (D18AP00053), the Cancer Research Institute, and the Simons Foundation for Autism Research Initiative.
A USC study reveals that plants use their circadian clocks and a specific protein, ABF3, to manage environmental stress, offering new approaches to develop crops resistant to drought and soil salinity. This research paves the way for genetically improved crops, potentially boosting resilience and yield in the face of climate change. Recent research reveals that plants employ their internal circadian rhythms to adapt to fluctuations in water availability and salt levels, presenting a novel strategy for developing crops that can withstand drought conditions. Climate change is currently impacting agricultural productivity and could eventually pose a considerable risk to global food security. Developing crops that are more resilient, capable of withstanding conditions such as drought or elevated soil salinity, is becoming an urgent need. A new study from the Keck School of Medicine of USC, funded in part by the National Institutes of Health, reveals details about how plants regulate their responses to stress that may prove crucial to those efforts. Researchers found that plants use their circadian clocks to respond to changes in external water and salt levels throughout the day. That same circuitry—an elegant feedback loop controlled by a protein known as ABF3—also helps plants adapt to extreme conditions such as drought. The results were recently published in the journal Proceedings of the National Academy of Sciences. “The bottom line is plants are stuck in place. They can’t run around and grab a drink of water. They can’t move into the shade when they want to or away from soil that has excess salt. Because of that, they’ve evolved to use their circadian clocks to exquisitely measure and adapt to their environment,” said the study’s senior author, Steve A. Kay, PhD, University and Provost Professor of Neurology, Biomedical Engineering and Quantitative Computational Biology at the Keck School of Medicine and Director of the USC Michelson Center for Convergent Bioscience. Bioluminescent image of Arabidopsis seedlings expressing circadian clock reporter genes in response to water stress.” Credit: Dr. Tong Liang/ Kay laboratory, USC The findings build on a long line of research from Kay’s lab on the role of circadian clock proteins in both plants and animals. Clock proteins, which regulate biological changes over the course of the day, may provide a shrewd solution to an ongoing challenge in crop engineering. Creating drought-resistant plants is difficult, because plants respond to stress by slowing their own growth and development—an overblown stress response means an underperforming plant. “There’s a delicate balance between boosting a plant’s stress tolerance while maximizing its growth and yield,” Kay said. “Solving this challenge is made all the more urgent by climate change.” Finding the feedback loop Previous plant biology research showed that clock proteins regulate about 90% of genes in plants and are central to their responses to temperature, light intensity and day length, including seasonal changes that determine when they flower. But one big outstanding question was whether and how clock proteins control the way plants handle changing water and soil salinity levels. To explore the link, Kay and his team studied Arabidopsis, a plant commonly used in research because it is small, has a rapid life cycle, a relatively simple genome and shares common traits and genes with many agricultural crops. They created a library of all of the more than 2000 Arabidopsis transcription factors, which are proteins that control the way genes are expressed under different circumstances. Transcription factors can provide key insights about regulation of biological processes. The researchers then built a data analysis pipeline to analyze each transcription factor and search for associations. “We got a really big surprise: that many of the genes the clock was regulating were associated with drought responses,” Kay said, particularly those controlling the hormone abscisic acid, a type of stress hormone that plants produce when water levels are very high or very low. The analysis revealed that abscisic acid levels are controlled by clock proteins as well as the transcription factor ABF3 in what Kay calls a “homeostatic feedback loop.” Over the course of a day, clock proteins regulate ABF3 to help plants respond to changing water levels, then ABF3 feeds information back to clock proteins to keep the stress response in check. That same loop helps plants adapt when conditions become extreme, for instance during a drought. Genetic data also revealed a similar process for handling changes in soil salinity levels. “What’s really special about this circuit is that it allows the plant to respond to external stress while keeping its stress response under control, so that it can continue to grow and develop,” Kay said. Engineering better crops The findings point to two new approaches that may help boost crop resilience. For one, agricultural breeders can search and select for naturally occurring genetic diversity in the circadian ABF3 circuit that gives plants a slight edge in responding to water and salinity stress. Even a small increase in resilience could substantially improve crop yield on a large scale. Kay and his colleagues also plan to explore a genetic modification approach, using CRISPR to engineer genes that promote ABF3 in order to design highly drought-resistant plants. “This could be a significant breakthrough in thinking about how to modulate crop plants to be more drought resistant,” Kay said. Reference: “The interplay between the circadian clock and abiotic stress responses mediated by ABF3 and CCA1/LHY” by Tong Liang, Shi Yu, Yuanzhong Pan, Jiarui Wang and Steve A. Kay, 6 February 2024, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2316825121 This work is supported by National Institute of General Medical Sciences of the National Institutes of Health [R37 GM067837].
DVDV1551RTWW78V
Pillow OEM factory for wellness brands 》ready to support your next launch with full-process expertiseFlexible manufacturing OEM & ODM factory Taiwan 》where quality, comfort, and credibility come togetherIndonesia OEM factory for footwear and bedding 》your trusted source for functional product development